Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults

Inclusion Criteria:

- Not of reproductive potential, or of reproductive potential and agrees to avoid
becoming pregnant or impregnating a partner for 2 months following study vaccination.

Exclusion Criteria:

- Is currently participating in or has participated in an interventional clinical trial
with an investigational compound or device within 90 days of participation in this
trial.

- Has previously been randomized in another clinical trial and received V920 or any
other Ebola vaccine.

- Has been exposed to Ebola virus at any time prior to study entry.

- Is pregnant or breastfeeding or plans to conceive within 2 months following study
vaccination.

- Has direct household exposure to a pregnant or lactating woman at the time of
participation in this trial.

- Has known or suspected impairment of immunological function (e.g., HIV positive).

- Has direct household exposure to a person with known or suspected impairment of
immunological function (e.g., HIV positive).

- Has a clinically significant history of intravenous (IV) drug abuse within 12 months
prior to study entry.

- Has a known allergy/sensitivity or contraindication to investigational product(s) or
its/their excipients (e.g., albumin).

- Has a history of malignancy <=5 years prior to study entry except for adequately
treated basal cell or squamous cell skin cancer or in situ cervical cancer.

- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or
child) who is investigational site or sponsor staff directly involved with this
trial.